Oppenheimer analyst Leland Gershell reiterated a Buy rating on Argenx Se (ARGX – Research Report) today and set a price target of $704.00. The ...

The breast cancer market has experienced robust growth, fueled by increased awareness and early detection efforts. Advances in diagnostic and treatme ...

About a dozen drugmakers are developing new weight-loss treatments aimed at preserving muscle, and industry analysts, ...

About a dozen drugmakers are developing new weight-loss treatments aimed at preserving muscle, and industry analysts, ...

Doctors say drugs that improve muscle mass could benefit older or infirm people at greater risk of falls and fractures ...

Veru Veru's oral drug, enobosarm, targets the androgen hormones that play a role in body development and reproductive health.

Veru Veru’s oral drug, enobosarm, targets the androgen hormones that play a role in body development and reproductive health.

Veru Inc. (NASDAQ:VERU – Get Free Report) was the recipient of a large increase in short interest in the month of January.As of January 31st, there was short interest totalling 14,620,000 shares ...

Dan Veru, CIO at Palisade Capital, says tariffs are negotiation tools, with companies adapting, though lower-margin businesses feel the strain despite a strong dollar.

Veru Inc (NASDAQ:VERU) reported positive top-line results from its Phase 2B clinical study for Novosarm, showing significant preservation of lean body mass in older patients. The company ...